A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology

Hemodialysis International

Volumn 13, Issue 3, 2009, Pages 360-362

  Block, Geoffrey A ^a   Persky, Martha S ^a   Ketteler, Markus ^b   Kestenbaum, Bryan ^c   Thadhani, Ravi ^d   Kooienga, Laura ^a   Spiegel, David ^e   Asplin, John ^f   Ehrlich, James ^e   Dennis, Vincent ^g   Nissenson, Allen ^h   Chertow, Glenn M ⁱ   Wheeler, David C ^j  

^a Denver Nephrologists   (United States)

^b KLINIKUM COBURG   (Germany)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f LithoLink Corporation   (United States)

^g Ambulatory Services of America   (United States)

^h DAVITA INC   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACETATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER; VITAMIN D;

CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIALYSIS; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TRANSPLANTATION; LETTER; MORTALITY; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PHOSPHORUS; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 69249189797     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00387.x     Document Type: Letter

References (11)

1. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71:438-441.
2. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72:1130-1137.
3. Giachelli CM. Vascular calcification: In vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol. 2003; 14(Suppl 4):S300-S304.
4. Shanahan CM. Mechanisms of vascular calcification in renal disease. Clin Nephrol. 2005; 63:146-157.
5. Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004; 19:1489-1496.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(Suppl 3):S1-S201.
7. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16:520-528.
8. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112:2627-2633.
9. Chonchol M, Dale R, Schrier RW, et al. Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med. 2009; 122:380-386.
10. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007; 167:879-885.
11. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976; 294:184-188.